Insect Cell Culture Media
Vigor Series Serum-free Media for Insect Cells
Shanghai BioEngine Sci-Tech Co., Ltd. developed the Tac series BHK cell medium, a serum-free medium suitable for BHK cell culture in laboratory research and large-scale production of suspension cultures. It facilitates the rapid growth and efficient replication of various viruses such as pseudorabies viruses, rabies viruses, and Newcastle disease viruses.Description
Performance
Features
Serum-free
Animal-derived component-free
Protein-free
Available for high-density culture of insect cells
Available for high protein expression in insect cells
Available in powder and liquid format
Suitable for both Sf9 and High five cells
Advantages
Animal-derived component-free; TSE/BSE statement available on demand
Distinctive culture results proven in numerous studies
Optional powder media for use in large-scale manufacturing with easy preparation procedures
Powder media capable of a single batch size of 60,000 L
Excellent inter-batch consistency (CPK*>1.33)
EU certified ISO13485:2016 QMS and MDSAP (FDA), all data are traceable
Complete clinical application supporting documents can be provided
*CPK: Process Capability Index. CPK>1.33 indicates good process control and small inter-batch difference of products.

Order Information
Basal Medium
|
Application |
Product Name |
Cat. No. |
Size |
Form |
Product Instruction (pdf) |
|
|
Suitable for both Sf9 and High five cells Support the production of subunit vaccine such as Porcine circovirus, Classical Swine Fever virus, and Porcine parvovirus or VLP |
Vigor-S 100S Insect Cell Serum-free Medium | EXP0109403 |
100 L |
Powder |
||
| EXP0109402 |
5 L |
Powder |
||||
| Vigor-S 100S Additive | EXP0109501 |
100 ml |
Liquid |
|||
| EXP0109502 |
5 ml |
Liquid |
||||
|
Suitable for both Sf9 and High five cells Support the production of subunit vaccines such as COVID-19, influenza and other VLPs |
Vigor-S101 Insect Cell Serum-free Medium | EXP0118601 |
1 L |
Liquid |
||
| Vigor-S101S Insect Cell Serum-free Medium | EXP0107404 |
100 L |
Powder |
|||
| EXP0107403 |
5 L |
Powder |
||||
| Vigor-S 101S Additive | EXP0107501 |
100 ml |
Liquid |
|||
| EXP0107503 |
5 ml |
Liquid |
Performance
Vaccines
In Vigor-S101S insect cell serum-free medium, cells were inoculated at a density of 1×106 cells/ml and passaged every 48 hours. Sf9 cell density reached 3-5×106 cells/ml (with a doubling time of 21-30 h), and High five cell density reached 5-7×106 cells/ml (with a doubling time of 17-21 h).
Vigor-S101S medium supports long-term stable passaging of both SF9 and High five cells.

In Vigor-S101S serum-free medium, Sf9 cells achieved a maximum viable cell density (VCD) of 12-14×106 cells/ml, with a faster growth rate, higher density, and longer maintenance time than in a well-known culture medium.
High five cells reached a maximum VCD of 9-11×106 cells/ml, comparable to a well-known medium specifically designed for High five cell culture.
In Vigor-S101S serum-free medium, the titer of baculovirus produced by Sf9 cells are superior to similar serum-free media products available in the market. outperformed similar products on the market in terms of titer when using Sf9 cells to produce baculovirus.

In High five cells, Vigor-S101S serum-free medium demonstrates an advantage in protein yield compared to other culture medium products.

Documents
Insect Cell Culture Media
DownloadFAQ
Q1:Why do we use insect cells for protein expression?
Q2:What are the cell platforms for AAV production?
Q3:What is gene therapy?
Q4:What are the advantages of cell-based vaccine production?
Q5:What medium do CHO cells use?
Q6: What is different between RPMI and DMEM?
Q7:How to prevent cell contamination and cross-contamination?
Previous
No InformationNext
No InformationHot Tags: insect cell culture media, China insect cell culture media manufacturers, suppliers, factory
Antibodies
In fed-batch process, CHO cells cultured in Eden CD CHO media demonstrate higher viable cell density (VCD) and protein production than competitors. On average, the antibody titers of various CHO cell lines cultured in Eden CD CHO media ranged from 2 to 11 g/L.

In the pulse perfusion process, CHO cells cultured in Eden CD CHO media demonstrated superior performance than competitive global brands. When VVD=1.0, volumetric productivity (Vp) can reach up to 2.2 g/L/day, and the cumulative product expression in 14 days can reach 19 g/L, 55% higher than global brand B. When VVD=2.0, Vp can reach up to 3.3g/L/day, and the cumulative product expression in 14 days can reach 25 g/L.

Brochures
| CHO Cell Medium |
FAQ
Q1: What is the packaging for BioEngine's powder media?
Q2: Can we seal the bag if there is leftover powdered medium?
Q3: What is the shelf life of BioEngine's Eden series CHO cell culture media, and how do you verify the expiration date?
Q4: Does BioEngine offer any regulators or additives for modulating antibody glycosylation?
Q5: Does BioEngine's CHO cell culture media contain hydrolysates, insulin, cytokines, or other components?
Q6: What are CHO media?
Q7: What are the differences between DMEM and RPMI?
1. Nutrient composition: DMEM (Dulbecco's Modified Eagle's Medium) and RPMI (Roswell Park Memorial Institute) have different nutrient compositions. DMEM contains higher levels of glucose, amino acids, vitamins, and sodium pyruvate, while RPMI has a lower glucose concentration and a different amino acid and vitamin composition.
2. pH: DMEM has a higher pH (7.4-7.6) compared to RPMI (7.2-7.4).
3. Usage: DMEM is a more general-purpose medium and can be used for a wide range of cell types, including adherent and non-adherent cells, while RPMI is typically used for the culture of immune cells such as lymphocytes and hybridomas.
4. Serum requirement: RPMI is often used with lower serum concentrations (e.g. 5-10%) than DMEM, which may require higher serum concentrations (e.g. 10-20%).
Overall, the choice between DMEM and RPMI depends on the specific cell type being cultured and the experimental conditions.
Q8: What is a fed-batch culture?
The goal of a fed-batch culture is to maximize cell growth and productivity while maintaining a stable culture environment. By controlling the rate and timing of nutrient addition, the culture can be kept in a state of controlled growth, avoiding the depletion of nutrients and accumulation of waste products that can limit growth and product formation in batch cultures. Additionally, the use of a fed-batch culture can allow for the accumulation of high cell densities and the optimization of production conditions, leading to higher yields and greater efficiency in bioprocesses.
Q9: What are the advantages of suspension cell cultures?
1. Scalability: Suspension cell cultures can be easily scaled up to produce large quantities of cells. This makes them particularly useful for biomanufacturing and the production of recombinant proteins.
2. Flexibility: Suspension cultures can be adapted to a wide range of culture conditions, such as pH, temperature, and nutrient availability. This allows for the optimization of cell growth and productivity.
3. Homogeneity: Suspension cultures provide a more homogeneous population of cells than adherent cultures, where cells may exhibit varying degrees of differentiation and proliferation.
4. Reduced risk of contamination: Suspension cultures are less prone to contamination by bacteria or fungi than adherent cultures, as there are no surfaces for microorganisms to adhere to.
5. Ease of harvesting: Cells in suspension culture can be easily harvested using centrifugation, filtration, or other methods. This simplifies downstream processing and reduces the risk of damage to the cells.
Overall, suspension cell culture offers several advantages over other types of cell culture, particularly in the context of large-scale biomanufacturing and the production of recombinant proteins.
Q10: What is gene therapy?
●Replacing a disease-causing gene with a healthy copy of the gene.
●Inactivating or deleting a disease-causing gene.
●Introducing a new or modified gene to help fight disease.
Gene therapy is a promising and innovative field of medicine that has potential applications for many diseases, such as cancer, genetic disorders, infectious diseases, and autoimmune diseases 23. However, gene therapy also faces many challenges and risks, such as safety, efficacy, ethical issues, and regulatory hurdles.
Gene therapy usually be delivered to the cells by virus vector, such as AAV, Adv and RV. BioEngine provides vigor series insect cell media for large scale AAV production."
Q11: Does BioEngine provides serum products, like FBS?
Previous
No InformationNext
Sf9 MediaSend Inquiry
Provide high quality culture media for research institutions, biopharmaceutical companies and clinical trial institutions, etc.
I agree to receive other communications from BioEngine which may contain technical or marketing information from this organization. You can unsubscribe from these communications at any time.
By submitting this form, you are agreeing to the terms and conditions of our Privacy Policy
You Might Also Like









